Report Detail
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market 2026 by Company, Regions, Type and Application, Forecast to 2032
- RnM4767529 |
- 29 October, 2026 |
- Global |
- 60 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.
This report is a detailed and comprehensive analysis for global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size and forecasts, in consumption value ($ Million), 2021-2032
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1 Agonists for the Treatment of both Diabetes and Obesity
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Semaglutide
Liraglutide
Tirzepatide
Market segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Market segment by players, this report covers
Novo Nordisk
Eli Lilly
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe GLP-1 Agonists for the Treatment of both Diabetes and Obesity product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, with revenue, gross margin, and global market share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity from 2021 to 2026.
Chapter 3, the GLP-1 Agonists for the Treatment of both Diabetes and Obesity competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and GLP-1 Agonists for the Treatment of both Diabetes and Obesity market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
Chapter 13, to describe GLP-1 Agonists for the Treatment of both Diabetes and Obesity research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Type
- 1.3.1 Overview: Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type in 2025
- 1.3.3 Semaglutide
- 1.3.4 Liraglutide
- 1.3.5 Tirzepatide
- 1.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
- 1.4.1 Overview: Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital and Clinic
- 1.4.3 Retail Pharmacies
- 1.4.4 Other
- 1.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size & Forecast
- 1.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast by Region
- 1.6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
- 1.6.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region, (2021-2032)
- 1.6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
- 1.6.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
- 1.6.5 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
- 1.6.6 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
- 1.6.7 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
2 Company Profiles
- 2.1 Novo Nordisk
- 2.1.1 Novo Nordisk Details
- 2.1.2 Novo Nordisk Major Business
- 2.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
- 2.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Novo Nordisk Recent Developments and Future Plans
- 2.2 Eli Lilly
- 2.2.1 Eli Lilly Details
- 2.2.2 Eli Lilly Major Business
- 2.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
- 2.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Eli Lilly Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Revenue
- 3.2.2 Top 3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
- 3.2.3 Top 6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
- 3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Overall Company Footprint Analysis
- 3.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Region Footprint
- 3.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Type Footprint
- 3.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
- 5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2026)
- 5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast by Application (2027-2032)
6 North America
- 6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
- 6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2032)
- 6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
- 6.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
- 6.3.2 United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 6.3.3 Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 6.3.4 Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7 Europe
- 7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
- 7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
- 7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
- 7.3.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
- 7.3.2 Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 7.3.3 France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 7.3.5 Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 7.3.6 Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8 Asia-Pacific
- 8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region
- 8.3.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2032)
- 8.3.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 8.3.3 Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 8.3.4 South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 8.3.5 India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 8.3.7 Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
9 South America
- 9.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
- 9.2 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
- 9.3 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
- 9.3.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
- 9.3.2 Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 9.3.3 Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10 Middle East & Africa
- 10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
- 10.3.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
- 10.3.2 Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
- 10.3.4 UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
11 Market Dynamics
- 11.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
- 11.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
- 11.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Chain
- 12.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Upstream Analysis
- 12.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Midstream Analysis
- 12.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on GLP-1 Agonists for the Treatment of both Diabetes and Obesity. Industry analysis & Market Report on GLP-1 Agonists for the Treatment of both Diabetes and Obesity is a syndicated market report, published as Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
